Complementary inhibition of synoviocyte, smooth muscle cell or mouse lymphoma cell proliferation by a vanadyl curcumin complex compared to curcumin alone.
A novel vanadyl curcumin complex (VO(cur)2) has been synthesized and and its physicochemical properties characterized. Biological characterization included in vitro testing for anti-rheumatic activity in synoviocytes, angiogenesis inhibition in smooth muscle cells and anti-cancer potential in mouse lymphoma cells; as well as in vivo testing for hypoglycemic activity by oral gavage in streptozotocin (STZ)-diabetic rats. VO(cur)2 was more effective as an anti-cancer agent, compared to uncomplexed curcumin or vanadyl ion alone, was more than twice as effective as curcumin alone as an anti-arthritic agent, and was more than four times as effective as curcumin alone in inhibiting smooth muscle cell proliferation. In both acute and chronic screening tests, VO(cur)2 was ineffective as an insulin mimetic agent; however, it also proved to be exceptionally non-toxic, with no evidence of negative symptomatology during a month-long treatment period, at doses up to and including 2.0 mmol kg(-1) day(-1).
Thompson
Katherine H
KH
Medicinal Inorganic Chemistry Group, Chemistry Department, University of British Columbia, 2036 Main Mall, Vancouver, BC, Canada V6T 1Z1. kthompson@chem.ubc.ca
Böhmerle
Karin
K
Polishchuk
Elena
E
Martins
Candice
C
Toleikis
Philip
P
Tse
Jeremy
J
Yuen
Violet
V
McNeill
John H
JH
Orvig
Chris
C
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D001786:Blood Glucose / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D045744:Cell Line, Tumor; D002470:Cell Survival; D003474:Curcumin / Q000494:pharmacology* / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006131:Growth Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007939:Leukemia L1210 / Q000188:drug therapy*; D008297:Male; D051379:Mice; D015394:Molecular Structure; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar; D013583:Synovial Membrane / Q000166:cytology / Q000187:drug effects*; D014638:Vanadates / Q000494:pharmacology* / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D001786:Blood Glucose; D006131:Growth Inhibitors; D007004:Hypoglycemic Agents; D014638:Vanadates; D003474:Curcumin